Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
A look at the supply chain that results in very high costs for HIV and hepatitis C medications.
Nevertheless, researchers advise careful kidney monitoring when pairing the medications.
The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).
Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.